CliffBio
biologic

Bimzelx

bimekizumab-bkzx

Loss of exclusivityOctober 2036projected — 12-year biologic exclusivity estimate
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameBimzelx
Active ingredientbimekizumab-bkzx
Strength320MG/2ML (160MG/2ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2024
Marketing statusRx

More from UCB

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bimzelx patent cliff — loss of exclusivity October 2036 | CliffBio